VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528
Titel:
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528
Auteur:
Gautschi, Oliver Dingemans, Anne-Marie Crowe, Susanne Peters, Solange Roder, Heinrich Grigorieva, Julia Roder, Joanna Zappa, Francesco Pless, Miklos Brutsche, Martin Baty, Florent Bubendorf, Lukas Hsu Schmitz, Shu-Fang Na, Kyung-Jae Carbone, David Stahel, Rolf Smit, Egbert